Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection

The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Natasha M., Janaka, Sanath Kumar, Hartman, William, Stramer, Susan, Goodhue, Erin, Weiss, John, Evans, David T., Connor, Joseph P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903276/
https://www.ncbi.nlm.nih.gov/pubmed/35259162
http://dx.doi.org/10.1371/journal.pone.0257930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903276/
https://www.ncbi.nlm.nih.gov/pubmed/35259162
http://dx.doi.org/10.1371/journal.pone.0257930

Ejemplares similares